Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions in vasodilator therapy for heart failure.

J N Cohn1

  • 1Department of Medicine, University of Minnesota Medical School, Minneapolis.

American Heart Journal
|March 1, 1991
PubMed
Summary

Vasodilator drugs improve heart function in heart failure. New agents like Flosequinan offer dual arterial and venous relaxation, potentially benefiting patients with heart failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.

Journal of human hypertension·2012
Same author

Rationale for angiotensin II receptor blocker therapy in chronic heart failure.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2007
Same author

Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.

Journal of human hypertension·2005
Same author

Angiotensin receptor blockers and clinical trials in heart failure.

European heart journal·2003
Same author

Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD).

Vascular medicine (London, England)·2002
Same author

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.

Congestive heart failure (Greenwich, Conn.)·2002

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Vasodilator therapy is crucial for managing left ventricular function in heart failure.
  • Current vasodilators have limitations, necessitating exploration of new therapeutic agents.
  • Ideal long-term heart failure drugs require specific pharmacodynamic effects, including reduced ejection impedance and slowed dysfunction progression.

Purpose of the Study:

  • To review the role of vasodilator therapy in heart failure.
  • To discuss the pharmacodynamic effects of ideal vasodilator drugs.
  • To explore the potential of new agents, such as Flosequinan, in heart failure treatment.

Main Methods:

  • Review of existing literature on vasodilator therapy in heart failure.
  • Discussion of pharmacodynamic effects and mechanisms of action.
  • Evaluation of combined vasodilator therapy strategies.

Main Results:

  • No single vasodilator is currently ideal for heart failure or hypertension.
  • Combined vasodilator therapy is a rationale approach due to complex vasoconstrictor mechanisms.
  • Flosequinan exhibits dual arterial and venous relaxation, suggesting potential benefits.

Conclusions:

  • Development of drugs with multiple mechanisms of action is therapeutically attractive.
  • Flosequinan's ability to relax both arterial and venous beds may offer significant advantages in heart failure management.
  • Further research into Flosequinan's cellular mechanisms is warranted.

Related Experiment Videos